Tibet Salt Reduction Study

Using Salt Substitute to Reduce Population Blood Pressure in Tibet: Tibet Salt Reduction Study

1. Research background

   - High blood pressure is one of the most important risk factors to cardiovascular diseases (CVDs). Reducing population blood pressure can control CVD incidence and lower mortality effectively. Much research has proven that adjusting for Na and K intake level can reduce blood pressure. According to the China Salt Substitute Study, the systolic blood pressure of intervention group which used salt substitute is 5.4 mmHg lower than that of control group. Life expectancy in Tibet is 67 years old. It is estimated that the use of salt substitute among population in Tibet can reduce total mortality in Tibet by 20%. China Salt Substitute Study in Tibet (CSSS-Tibet), found that salt substitute is effective in lowering both systolic and diastolic blood pressure and offers a simple, low-cost approach for hypertension control among Tibetans in China (unpublished results). However, the study focused on hypertensive patients, the effectiveness of hypertension control by providing free salt substitute to the entire population remains unknown, and a large-scale trial is needed.

2. Objectives

   - Primary objective is to observe the effect of providing salt substitute on population blood pressure in Tibet. Secondary objective is to observe the effect of such intervention on population mortality, cardiovascular mortality and life expectancy. In addition, the data collected from high-risk population (sub-group) in the study will be used in China Salt Substitute and Stroke Study (SSaSS). Also, serum cholesterol and random blood glucose of people over 60 in Tibet will be collected.

3. Method

   • The study is a open, cluster-randomized, controlled trial.
   • 30 villages with 15 to 35 households each and a distance of at least five kilometers in between will be selected from Damxung county and Maizhokunggar county. The two counties have an average altitude of over 4000 meters in Tibet Autonomous Region.
   • All selected villages will be randomly assigned to intervention group or control group on a 1:1 ratio.
   • All household in the selected villages will be recruited if they meet the eligibility criteria. Approximately 4,500 participants will be enrolled
   • Intervention group receives free salt substitute. Control group will continue to buy their own normal salt. Both group will receive the same health education on salt reduction.
4. Outcome - Primary outcome is blood pressure. Secondary outcomes include total mortality, cardiovascular disease mortality, life expectancy, serum cholesterol level of people over 60, and random blood glucose level of people over 60.

Study Overview

• Status: Unknown
• Conditions: Cardiovascular Diseases; Death; Blood Pressure
• Intervention / Treatment: Dietary supplement: salt substitute

• Study Type: Interventional
• Enrollment (Anticipated): 4500
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Tibet
    • Damxung, Tibet, China, 851500
    • Maizhokunggar, Tibet, China, 850200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• All family households in the selected satellite village will be invited to participate in the study

Family households will be excluded from participating if they meet one or more of the following exclusion criteria:

• Any member in the family is using a potassium-sparing diuretic
• Any member in the family is using a potassium supplement
• Any member in the family has serious renal impairment
• Any member in the family over 18 could not sign informed consent
• Life expectancy of any member in the family is shorter than 6 months in doctor's opinion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Salt Substitute; salt substitute	Dietary supplement: salt substitute; Free salt substitute provided
No Intervention: Control; Participants continue to buy salt at their own expense

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Difference in change from baseline in blood pressure between intervention and control	Baseline, 6,12, 24 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Difference in total mortality between intervention and control	6, 12, 24 months
Difference in cardiovascular disease mortality between intervention and control	6,12, 24 months
Difference in life expectancy between intervention and control group	6, 12, 24 months
The distribution of blood glucose level in population over 60 years old	baseline
Distribution of serum cholesterol level in population over 60 years old	baseline

Collaborators and Investigators

• Sponsor: Beijing Jishuitan Hospital
• Collaborators: Peking University; The George Institute for Global Health, Australia; The George Institute for Global Health at PUHSC; Science and Technology Department of Ningxia; People's Hospital of Tibet; People's Hospital of Maizhokunggar; Tibet University; People's Hospital of Damxung County, Tibet
• Investigators: Principal Investigator: Xingshan Zhao, M.D., Beijing Jishuitan Hospital

Study record dates

Study Major Dates

• Study Start: April 1, 2014
• Primary Completion (Anticipated): March 1, 2016

Study Registration Dates

• First Submitted: December 20, 2013
• First Submitted That Met QC Criteria: December 20, 2013
• First Posted (Estimate): December 27, 2013

Study Record Updates

• Last Update Posted (Estimate): January 10, 2014
• Last Update Submitted That Met QC Criteria: January 8, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases
• Other Study ID Numbers: 2013BAI05B04